RNA binding protein PUM2 promotes the stemness of breast cancer cells via competitively binding to neuropilin-1 (NRP-1) mRNA with miR-376a

Zhang, Lansheng; Chen, Yanwei; Li, Caihong; Liu, Jinyang; Ren, Huiwen; Li, Lishan; Zheng, Xia; Wang, Hui; Han, Zhengxiang

doi:10.1016/j.biopha.2019.108772

Cited by 32 publications

(32 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, the predicted top 5 miRNAs were verified by luciferase reporter activity assay, and 3 miRNAs including PUM2 were revealed to be downregulated by miR-376a-3p. Thirdly, PUM2 was reported to promote cell proliferation and metastasis in several cancer types (38,42). However, the other 2 miRNAs were not reported to be involved in cancer pathology and were therefore not selected.…”

Section: Discussionmentioning

confidence: 99%

LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p

Shen

Yinyin

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

Increasing research has demonstrated that lncRNAs participate in the development of multiple cancer types. However, the role of TTN-AS1 in endometrial cancer (EC) remains unknown. The present study aimed to explore the function of titin-antisense RNA1 (TTN-AS1) in EC progression and the underlying mechanisms. qRT-PCR was performed to assess the TTN-AS1 expression patterns in EC tissues and cell lines. Loss of function experiments were carried out to estimate the effects of TTN-AS1 on EC cell proliferation, migration and invasion. To reveal the underlying mechanisms, informatics tools were used to predict the targets. Rescue experiments were performed to investigate the TTN-AS1-regulated miR-376a-3p/pumilio homolog 2 (PUM2) axis involved. The results of the present study revealed that TTN-AS1 was highly expressed in both EC tissues and cell lines, and TTN-AS1 knockdown inhibited EC cell proliferation, migration and invasion. With respect to the mechanisms, miR-376a-3p was revealed to be targeted by TTN-AS1, and reversed the effects on EC development induced by TTN-AS1. In addition, PUM2 was positively regulated by TTN-AS1, and miR-376a-3p mediated the regulation between them. Furtherly, in vivo experiments confirmed the results. Collectively, TTN-AS1 enhanced EC cell proliferation and metastasis by targeting the miR-376a-3p/PUM2 axis, which may shed light on EC diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p

Shen

Yinyin

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…RBP dysregulation has been shown to be a hallmark of many tumor types [8]. In gliomas [10], breast cancer [11], and B-ALL [12] and dsRNA binding. It has been reported that human ribosomal protein S3 (RPS3) regulates the expression of silent information regulator 1 (SIRT1) after transcription to promote liver cancer [22].…”

Section: Discussionmentioning

confidence: 99%

“…The RBP Musashi1 (Msi1) has been shown to promote glioma progression when its normal interactions with miR-137 are disrupted [10]. PUM2 is an RBP that is overexpressed in breast cancer and to be negatively correlated with OS and a lack of tumor recurrence in these patients 4 [11]. The RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has similarly been found to be overexpressed in mixed-lineage leukemia-rearranged (MLL rearranged) Bacute lymphoblastic leukemia (B-ALL) and to be associated with poorer outcomes and higher recurrence risks in these patients [12].…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of an Rna Binding Protein-associated Prognostic Model for Hepatocellular Carcinoma

Wang

Huang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: Hepatocellular carcinoma (HCC) is among the deadliest forms of cancer. While RNA-binding proteins (RBPs) have been shown to be key regulators of oncogenesis and tumor progression, their dysregulation in the context of HCC remains to be fully characterized. Methods: Data from the Cancer Genome Atlas - liver HCC (TCGA-LIHC) database were downloaded and analyzed in order to identify RBPs that were differentially expressed in HCC tumors relative to healthy normal tissues. Functional enrichment analyses of these RBPs were then conducted using the GO and KEGG databases to understand their mechanistic roles. Central hub RBPs associated with HCC patient prognosis were then detected through Cox regression analyses, and were incorporated into a prognostic model. The prognostic value of this model was then assessed through the use of Kaplan-Meier curves, time-related ROC analyses, univariate and multivariate Cox regression analyses, and nomograms. Lastly, the relationship between individual hub RBPs and HCC patient overall survival (OS) was evaluated using Kaplan-Meier curves. Results: In total, we identified 81 RBPs that were differentially expressed in HCC tumors relative to healthy tissues (54 upregulated, 27 downregulated). Seven prognostically-relevant hub RBPs (SMG5, BOP1, LIN28B, RNF17, ANG, LARP1B, and NR0B1) were then used to generate a prognostic model, after which HCC patients were separated into high- and low-risk groups based upon resultant risk score values. In both the training and test datasets, we found that high-risk HCC patients exhibited decreased OS relative to low-risk patients, with time-dependent area under the ROC curve values of 0.801 and 0.676, respectively. This model thus exhibited good prognostic performance. We additionally generated a prognostic nomogram based upon these seven hub RBPs and found that four other genes were significantly correlated with OS. Conclusion: We herein identified a seven RBP signature that can reliably be used to predict HCC patient OS, underscoring the prognostic relevance of these genes.

show abstract

“…RBP dysregulation has been shown to be a hallmark of many tumor types [8]. In gliomas [10], breast cancer [11], and B-ALL [12], RBPs have been found to be directly related to tumor development and patient prognosis. In the present study, we identi ed 81 RBPs that were differentially expressed in HCC tissues relative to healthy control tissues in the TCGA-LIHC dataset.…”

Section: Discussionmentioning

confidence: 99%

“…The RBP Musashi1 (Msi1) has been shown to promote glioma progression when its normal interactions with miR-137 are disrupted [10]. PUM2 is an RBP that is overexpressed in breast cancer and to be negatively correlated with OS and a lack of tumor recurrence in these patients [11]. The RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has similarly been found to be overexpressed in mixed-lineage leukemia-rearranged (MLL rearranged) B-acute lymphoblastic leukemia (B-ALL) and to be associated with poorer outcomes and higher recurrence risks in these patients [12].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma

Wang

Huang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is among the deadliest forms of cancer. While RNA-binding proteins (RBPs) have been shown to be key regulators of oncogenesis and tumor progression, their dysregulation in the context of HCC remains to be fully characterized.Methods: Data from the Cancer Genome Atlas - liver HCC (TCGA-LIHC) database were downloaded and analyzed in order to identify RBPs that were differentially expressed in HCC tumors relative to healthy normal tissues. Functional enrichment analyses of these RBPs were then conducted using the GO and KEGG databases to understand their mechanistic roles. Central hub RBPs associated with HCC patient prognosis were then detected through Cox regression analyses, and were incorporated into a prognostic model. The prognostic value of this model was then assessed through the use of Kaplan-Meier curves, time-related ROC analyses, univariate and multivariate Cox regression analyses, and nomograms. Lastly, the relationship between individual hub RBPs and HCC patient overall survival (OS) was evaluated using Kaplan-Meier curves. Finally, find protein-coding genes (PCGs) related to hub RBPs were used to construct a hub RBP-PCG co-expression network.Results: In total, we identified 81 RBPs that were differentially expressed in HCC tumors relative to healthy tissues (54 upregulated, 27 downregulated). Seven prognostically-relevant hub RBPs (SMG5, BOP1, LIN28B, RNF17, ANG, LARP1B, and NR0B1) were then used to generate a prognostic model, after which HCC patients were separated into high- and low-risk groups based upon resultant risk score values. In both the training and test datasets, we found that high-risk HCC patients exhibited decreased OS relative to low-risk patients, with time-dependent area under the ROC curve values of 0.801 and 0.676, respectively. This model thus exhibited good prognostic performance. We additionally generated a prognostic nomogram based upon these seven hub RBPs and found that four other genes were significantly correlated with OS.Conclusion: We herein identified a seven RBP signature that can reliably be used to predict HCC patient OS, underscoring the prognostic relevance of these genes.

show abstract

RNA binding protein PUM2 promotes the stemness of breast cancer cells via competitively binding to neuropilin-1 (NRP-1) mRNA with miR-376a

Cited by 32 publications

References 26 publications

LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p

LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p

Development and Validation of an Rna Binding Protein-associated Prognostic Model for Hepatocellular Carcinoma

Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma

Contact Info

Product

Resources

About